Aptabio Therapeutics KRX:293780KOSDAQ
압타바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Aptabio Therapeutics reported revenue of ₩1.6bn, up 42.8% year on year, and an operating loss of ₩3.6bn. Aptabio Therapeutics (압타바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Aptabio Therapeutics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.6bn | +42.8% | −₩3.6bn margin −223.0% | ₩1.1bn |
| Q1 2026 | ₩957m | +150.2% | −₩6.1bn | −₩6.4bn |
| Q4 2025 derived | ₩1.0bn | +34.6% | −₩5.7bn | −₩6.5bn |
| Q3 2025 | ₩1.2bn | +38.7% | −₩3.4bn margin −283.3% | −₩3.1bn |
| Q2 2025 | ₩1.1bn | +0.2% | −₩4.1bn | −₩4.2bn |
| Q1 2025 | ₩383m | -39.9% | −₩2.6bn | −₩2.6bn |
| Q4 2024 derived | ₩744m | +157.3% | −₩6.6bn | −₩10.4bn |
| Q3 2024 | ₩859m | +10147.5% | −₩5.9bn | −₩8.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aptabio Therapeutics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Aptabio Therapeutics news Korean headlines
No articles yet.